BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Queensland Health
Daiichi Sankyo
US Army

Generated: November 21, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,527,814

« Back to Dashboard

Summary for Patent: 5,527,814

Title: Use of 2-amino-6-(trifluoromethoxy)benzothiazole for obtaining a medicament for the treatment of amyotrophic lateral sclerosis
Abstract:Use of 2-amino-6-(trifluoromethoxy)benzothiazole, or a salt of this compound with a pharmaceutically acceptable acid, for obtaining a medicament intended for the treatment of motor neuron diseases, in particular amyotrophic lateral sclerosis, and especially amyotrophic lateral sclerosis with early bulbar involvement or the bulbar form of the disease.
Inventor(s): Louvel; Erik (Manosque, FR)
Assignee: Rhone Poulenc Rorer S.A. (FR)
Application Number:08/327,343
Patent Claim Types:
see list of patent claims
Use; Composition;

No matches for this query

Foreign Priority and PCT Information for Patent: 5,527,814

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France92 02696Mar 06, 1992

International Patent Family for Patent: 5,527,814

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria149833► Subscribe
Australia2948292► Subscribe
Australia666150► Subscribe
Canada2117466► Subscribe
Czech Republic281293► Subscribe
Czech Republic9402120► Subscribe
Germany69218255► Subscribe
Denmark0627919► Subscribe
European Patent Office0558861► Subscribe
European Patent Office0627919► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
US Army
Fish and Richardson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus